Tefibazumab

Tefibazumab
Monoclonal antibody
Type	Whole antibody
Source	Template:Infobox drug/mab source
Target	Clumping factor A
Identifiers
CAS Number	521079-87-8
ATC code	none
Chemical data
Formula	C6548H10122N1730O2034S44
Molar mass	147.590 kDa[[Script error: No such module "String".]]

Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Tefibazumab (marketed under the brand name Aurexis) is a humanized monoclonal antibody for the treatment of severe infections with Staphylococcus aureus. Possible indications include the treatment of S. aureus in patient with cystic fibrosis^[1] and of methicillin-resistant S. aureus.^[2]

It was developed by Inhibitex.^[3]

References

Cite error: Invalid <references> tag; parameter "group" is allowed only.

Use <references />, or <references group="..." />

This monoclonal antibody-related article is a stub. You can help ssf by expanding it.

↑ ClinicalTrials.gov NCT00198289
↑ Pan; Lorenzotti, S; Zoncada, A (2008). "Registered and investigational drugs for the treatment of methicillin-resistant Staphylococcus aureus infection". Recent patents on anti-infective drug discovery. 3 (1): 10–33. doi:10.2174/157489108783413173. PMID 18221183. edit
↑ John JF (2006). "Drug evaluation: tefibazumab--a monoclonal antibody against staphylococcal infection". Curr. Opin. Mol. Ther. 8 (5): 455–60. PMID 17078388.

v t e Humanized monoclonal antibodies ("-zu-")
"-tuzu-" (tumor)	Afutuzumab, Alemtuzumab, Bevacizumab, Bivatuzumab mertansine, Cantuzumab mertansine, Citatuzumab bogatox, Dacetuzumab, Elotuzumab^†, Etaracizumab, Farletuzumab, Gemtuzumab ozogamicin, Inotuzumab ozogamicin, Labetuzumab, Lintuzumab, Matuzumab^§, Milatuzumab, Nimotuzumab, Oportuzumab monatox, Pertuzumab, Sibrotuzumab, Tacatuzumab tetraxetan, Tigatuzumab, Trastuzumab, Tucotuzumab celmoleukin, Veltuzumab
"-lizu-" (immune system)	immunosuppressive: Aselizumab, Apolizumab, Benralizumab^†, Cedelizumab, Certolizumab pegol, Daclizumab, Eculizumab, Efalizumab, Epratuzumab, Erlizumab, Fontolizumab, Mepolizumab, Natalizumab, Ocrelizumab, Omalizumab, Pascolizumab, Pexelizumab, PRO 140^†, Reslizumab, Rontalizumab, Rovelizumab, Ruplizumab, Siplizumab, Talizumab, Teplizumab, Tocilizumab, Toralizumab, Vedolizumab, Visilizumab, TGN1412^§ non-immunosuppressive: Ibalizumab^†
"-bazu-" (bacterial)	Tefibazumab^†
"-cizu-" (cardiovascular)	Alacizumab pegol, Bevacizumab/Ranibizumab, Etaracizumab, Tadocizumab
"-nezu-"/"-neuzu-" (nervous system)	Bapineuzumab^†, Solanezumab, Tanezumab
"-toxazu-" (toxin as target)	Urtoxazumab
"-vizu-" (viral)	Felvizumab, Motavizumab, Palivizumab
"-kizu-" (interleukin as target)	Lebrikizumab
"-anibizu-" (angiogenesis inhibitor)	Ranibizumab
^†Undergoing clinical trials. ^§Never marketed.